...
首页> 外文期刊>International Journal of Nanomedicine >Formation of ion pairing as an alternative to improve encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles
【24h】

Formation of ion pairing as an alternative to improve encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles

机译:形成离子对作为替代方法,以改善固体脂质纳米粒中负载的全反式维甲酸的包封和抗癌活性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Abstract: This work aims to develop solid lipid nanoparticles (SLNs) loaded with retinoic acid (RA) to evaluate the influence of two lipophilic amines, stearylamine (SA) and benethamine (BA), and one hydrophilic, triethylamine (TA), on drug-encapsulation efficiency (EE) and cytotoxicity in cancer cell lines. The SLNs were characterized for EE, size, and zeta potential. The mean particle size decreased from 155 ± 1 nm (SLNs without amine) to 104 ± 4, 95 ± 1, and 96 ± 1 nm for SLNs prepared with SA, BA, and TA, respectively. SA-RA-loaded SLNs resulted in positively charged particles, whereas those with TA and BA were negatively charged. The EEs were significantly improved with the addition of the amines, and they increased from 36% ± 6% (without amine) to 97% ± 2%, 90% ± 2%, and 100% ± 1% for SA, TA, and BA, respectively. However, stability studies showed higher EE for BA-RA-loaded SLNs than TA-RA-loaded SLNs after 30 days. The formulations containing SA loaded or unloaded (blank SLNs) with RA were cytotoxic in normal and cancer cell lines. In contrast, the blank SLNs containing TA or BA did not show cytotoxicity in human breast adenocarcinoma cells (MCF-7), while RA-loaded SLNs with the respective amines were significantly more cytotoxic than free RA. Furthermore, the cytotoxicity of BA-RA-loaded SLNs was significantly higher than TA-RA-loaded SLNs. These findings are in agreement with the data obtained in the evaluation of subdiploid DNA content and cell-cycle analysis, which showed better anticancer activity for BA-RA-loaded SLNs than TA-RA-loaded SLNs and free RA. Taken together, these findings suggest that the BA-RA-loaded SLN formulation is a promising alternative for the intravenous administration of RA in the treatment of cancer.
机译:摘要:这项工作旨在开发负载视黄酸(RA)的固体脂质纳米颗粒(SLN),以评估两种亲脂性胺硬脂胺(SA)和苯乙胺(BA)以及一种亲水性三乙胺(TA)对药物的影响-封装效率(EE)和癌细胞系中的细胞毒性。 SLN的EE,尺寸和Zeta电位均经过表征。用SA,BA和TA制备的SLN的平均粒径分别从155±1 nm(不含胺的SLN)降至104±4、95±1和96±1 nm。装有SA-RA的SLN导致带正电的颗粒,而带有TA和BA的则带负电。添加胺后,EE显着改善,对于SA,TA和SA,EE从36%±6%(不含胺)增加到97%±2%,90%±2%和100%±1%。 BA,分别。但是,稳定性研究表明,30天后,BA-RA装载的SLN的EE高于TA-RA装载的SLN。含有或不含SA的SA的制剂(空白的SLN)带有RA,在正常和癌细胞系中具有细胞毒性。相反,空白的含有TA或BA的SLN在人乳腺癌细胞(MCF-7)中未显示出细胞毒性,而RA负载的具有相应胺的SLN的细胞毒性明显高于游离RA。此外,BA-RA负载的SLNs的细胞毒性明显高于TA-RA负载的SLNs。这些发现与在亚二倍体DNA含量评估和细胞周期分析中获得的数据相一致,后者显示了载有BA-RA的SLN比载有TA-RA的SLN和游离RA更好的抗癌活性。综上所述,这些发现表明,BA-RA负载的SLN制剂是用于静脉内施用RA治疗癌症的有希望的替代方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号